Wolfe Research Initiates Peer Perform Rating for Tyra Biosciences (TYRA)

On May 19, Wolfe Research initiated a 'Peer Perform' rating for Tyra Biosciences Inc. (NASDAQ:TYRA) without setting a price target. The firm highlighted the potential of dabogratinib in treating low-risk non-muscle invasive bladder cancer while noting pending safety concerns.

By Fatima Gulzar Mon, June 1, 2026 at 11:03 AM GMT+3 1 min read · Yahoo Finance · June 1, 2026, 08:03 UTC

Wolfe Research Initiates Peer Perform Rating for Tyra Biosciences (TYRA)

Tickers: $TYRA

Topics: Biotechnology Investment Analysis Pharmaceuticals

Read the full article at Yahoo Finance

More World news

Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC
Oklo and Centrus Energy Sign Multi-Year HALEU Fuel Supply Agreements for Ohio Nuclear Campus Seeking Alpha · November 12, 2026, 17:28 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC
Nvidia CEO Jensen Huang Resigns Amid Investigation and Personal Allegations Motley Fool · November 12, 2026, 17:20 UTC
Argus Research Upgrades Republic Services to Buy Seeking Alpha · November 12, 2026, 17:16 UTC
Moderna Shares Decline Following Analyst Day Projections and Future Cost Concerns Motley Fool · November 12, 2026, 17:13 UTC
United Airlines Restricts AI Agent Access to Booking Systems Due to Cybersecurity and Regulatory Concerns TechCrunch · November 12, 2026, 17:17 UTC